zoliflodacin
Investigational antibiotic shows high cure rates in gonorrhoea at Phase 2
November 8, 2018Research and Development National Institute of Allergy and Infectious Diseases, National Institutes of Health, gonorrhoea, pharma, zoliflodacin
A Phase 2 study sponsored by The National Institute of Allergy and Infectious Diseases (NIAID), a branch of the National …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
